Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study.
暂无分享,去创建一个
T. Corcoran | J. Pilewski | A. Ceppe | S. Donaldson | F. Ratjen | S. Rowe | W. Bennett | B. Laube | P. Mogayzel | S. Sagel | J. Clancy | Pradeep G. Bhambhvani | Jihong Wu | P. Bhambhvani
[1] J. Clancy,et al. Clinical Effectiveness of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients Homozygous for F508del-CFTR. , 2020, Annals of the American Thoracic Society.
[2] P. Reix,et al. Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[3] J. Clancy,et al. Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[4] D. Dorahy,et al. Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[5] S. McColley,et al. Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[6] T. Corcoran,et al. Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR. , 2018, JCI insight.
[7] B. Tümmler,et al. Effects of Lumacaftor‐Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis , 2018, American journal of respiratory and critical care medicine.
[8] S. Stanojevic,et al. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. , 2017, The Lancet. Respiratory medicine.
[9] Linbo Liu,et al. Ion Channels and Transporters in Lung Function and Disease Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy , 2016 .
[10] A. Heinzmann,et al. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor. , 2015, American journal of respiratory and critical care medicine.
[11] Xiaohong Huang,et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.
[12] Umer Khan,et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. , 2014, American journal of respiratory and critical care medicine.
[13] J. Clancy,et al. Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation , 2013, PloS one.
[14] T. Corcoran,et al. Multisite comparison of mucociliary and cough clearance measures using standardized methods. , 2013, Journal of aerosol medicine and pulmonary drug delivery.
[15] Janet Stocks,et al. Consensus statement for inert gas washout measurement using multiple- and single- breath tests , 2013, European Respiratory Journal.
[16] Matthias Griese,et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.
[17] P. Negulescu,et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.
[18] J. Clancy,et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. , 2010, The New England journal of medicine.
[19] P. Negulescu,et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.
[20] ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. , 2005, American journal of respiratory and critical care medicine.